| Literature DB >> 33845125 |
Sónia Rocha1, Mariana Lucas1, Daniela Ribeiro1, M Luísa Corvo2, Eduarda Fernandes3, Marisa Freitas4.
Abstract
Diabetes mellitus is one of the biggest health emergencies of the 21st century worldwide, characterized by deficiency in insulin secretion and/or action, leading to hyperglycemia. Despite the currently available antidiabetic therapeutic options, 4.2 million people died in 2019 due to diabetes. Thus, new effective interventions are required. Polyphenols are plant secondary metabolites and have been recognized for their vast number of biological activities, including potential antidiabetic effects. However, the poor bioavailability and high metabolization of polyphenols restrict their biological effects in vivo. Nanotechnology is a promising area of research to improve the therapeutic effect of several compounds. Therefore, this review provides an overview of the literature about the utility of nano-based drug delivery systems as vehicles of polyphenols in diabetes treatment. It was possible to conclude that, in general, nano-based drug delivery systems can potentiate the beneficial antidiabetic properties of polyphenols, when compared with the free compounds, opening a new field of research in diabetology.Entities:
Keywords: Amentoflavone (PubChem CID: 5281600); Diabetes mellitus; Drug targeting; Fisetin (PubChem CID: 5281614); Gallic acid (PubChem CID: 370); Myricitrin (PubChem CID: 5281673); Nano-based drug delivery systems; Naringenin (PubChem CID: 932); Polyphenols; Quercetin (PubChem CID: 5280343); Resveratrol (PubChem CID: 445154); Rutin (PubChem CID: 5280805); Scutellarin (PubChem CID: 185617); Silybin (PubChem CID: 31553)
Mesh:
Substances:
Year: 2021 PMID: 33845125 DOI: 10.1016/j.phrs.2021.105604
Source DB: PubMed Journal: Pharmacol Res ISSN: 1043-6618 Impact factor: 7.658